PositoAI/ US/ Erasca, Inc.

Erasca, Inc.

NasdaqGS: ERAS · Healthcare

Positivity Index

#5,886 / 6,774

Global

#3,289 / 4,000

United States

Positivity Score

14,424

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

Erasca, Inc. — Overview & Financial Snapshot

Erasca, Inc. (NasdaqGS: ERAS) is a Healthcare company, ranked #5,886 of 6,774 companies globally and #3,289 of 4,000 in United States on PositoAI, with a Positivity Score of 14,424. Its market capitalisation is ₹46,352.11 Cr ($4.91B), P/E ratio is -14.8 and P/B ratio is 13.57. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #8 Impact BioMedical Inc. 26,149 #13 Onconetix, Inc. 25,902 #15 Revelation Biosciences, Inc. 25,780 #18 Vyome Holdings, Inc. 25,696

— Nothing to show —

OpenAI is reading recent news...

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

P/B Ratio 13.57

P/E Ratio -14.8

D/E Ratio 0.12

ROE -78.25%

Owes vs Owns ? 0.17× Low $0.17 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹-89.67$-0.95

Forward EPS ₹-58.82$-0.62

Beta 0.62

Market Cap ₹46,352.11 Cr$4.91B

What these numbers mean →

What does Erasca, Inc. do?

What is Erasca, Inc.'s P/E and P/B ratio?

Erasca, Inc. has a P/E ratio of -14.8 and a P/B ratio of 13.57.

What is Erasca, Inc.'s debt-to-equity ratio?

Erasca, Inc. has a debt-to-equity ratio of 0.12.

How much does Erasca, Inc. owe compared with what it owns?

Erasca, Inc. owes $0.17 for every $1 it owns (balance sheet Jun 2026), which is low.

What is Erasca, Inc.'s Positivity rank?

Erasca, Inc. is ranked #5,886 of 6,774 companies globally and #3,289 of 4,000 in United States on PositoAI, with a Positivity Score of 14,424.

Does Erasca, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Erasca, Inc..

Where can I read the latest news about Erasca, Inc.?

Recent headlines about Erasca, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Erasca, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Erasca, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.